ADP adoptive cell therapy

ADP adoptive cell therapy refers to a class of autologous T-cell therapies in which a patient’s own T lymphocytes are genetically engineered to express affinity-enhanced T-cell receptors (TCRs) targeting specific cancer antigens. Notable examples include ADP-A2M10 and ADP-A2M4CD8, which are designed to recognize MAGE-A10 and MAGE-A4 cancer testis antigens presented by HLA molecules on tumor cells. These therapies involve leukapheresis to collect patient T-cells, ex vivo genetic modification using lentiviral vectors to introduce the desired receptor specificity (and in some cases co-receptors like CD8α), expansion of the modified cells in vitro, and reinfusion into the patient following lymphodepleting chemotherapy. The mechanism of action is direct recognition and killing of tumor cells expressing the target antigen via enhanced antigen-specific cytotoxicity. Clinical trials have demonstrated acceptable safety profiles with evidence of anti-tumor activity in advanced solid tumors such as non-small cell lung cancer (NSCLC), urothelial carcinoma (UC), head and neck squamous cell carcinoma (HNSCC), melanoma, and others[4][6][8][10].

Brand names

Tecelra

Other names

adoptive cell therapyACTSPEAR T cells